Enanta Pharmaceuticals Inc. Common Stock (ENTA)

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; E…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

120

Website

www.enanta.com/

Fundamentals

1-day range

$13.48$13.91

Market cap

$376.57M

P/E (trailing)

—

P/E (forward)

-5.38

EPS (trailing)

$-2.41

Dividend yield

—

Beta

0.96

Avg. volume

214.7K

Forecasts

5 analyst ratings

Enanta Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $376.57MP/E —
  $7.05$17.15
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $391.42MP/E 18.65
  $4.3$9.51
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $351.32MP/E —
  $5.14$10.42
• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $349.38MP/E —
  $5.85$33.68
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
  Benzinga · 8/10/2026

• Scott T. Rottinghaus · August 8, 2026 · Tax Withholding

  1.5K @ $13.34
• Vance Terry · March 11, 2026 · Grant

  20.0K
• Russell Lesley · March 11, 2026 · Grant

  20.0K
• Peterson Kristine · March 11, 2026 · Grant

  20.0K
• Hata Yujiro S · March 11, 2026 · Grant

  20.0K
• Mark G. Foletta · March 11, 2026 · Grant

  20.0K
• CARTER BRUCE L A · March 11, 2026 · Grant

  20.0K

Institutional Ownership

March 31, 2026

Total shares held

25.57M

Total value held

$275.17M

Institutional holders

128